alli(R) Launching a New Chewable Tablet in 2011

LONDON, February 7, 2011 - GlaxoSmithKline (GSK) today announces that it has received a licence
extension for alli, the first pharmacy-only weight loss aid licensed for use
throughout Europe. This license extension is for new chewable tablets. The
new alli tablets are planned to be on sale in pharmacies throughout the UK in
April this year.

alli is for overweight adults with a BMI of 28 or more and can help boost
your weight loss compared with dieting alone. alli should be used with a
reduced calorie, lower-fat diet and blocks about 25% of the fat that you eat
from being absorbed. For every 2 lbs you work to lose, adding alli can help
you lose 1 lb more.

The new alli chewable tablets are discreet, pleasant tasting and easy to
take. With alli's free, personalised online support programme at
www.alli.co.uk, staying on track is simple and users can learn new
skills to help them reach a healthier weight.

alli brand manager Ruth Irving said: "Losing weight is challenging and
alli wants to encourage people to adopt a sensible approach to weight loss so
that they can achieve a healthier weight. We are pleased that we will soon be
able to offer people an alternative way to take alli, complemented by our
personalised online support programme, to help them reach their weight loss
goals."

alli, has been available in the UK since early 2009 and has helped over
120,000 people across the region to lose weight[1]. For those wanting to
kick-start a weight loss journey in January, alli 60 mg capsules are
available in pharmacies now.

alli is a trade mark of the GlaxoSmithKline group of companies

Notes to editor:

About alli

alli 27 mg chewable tablets and 60 mg capsules are weight loss aids
containing orlistat. For overweight adults with a BMI of 28 or more. Follow a
reduced calorie, lower-fat diet. Always read the label.

About GSK

GlaxoSmithKline (GSK), one of the world's leading research-based
pharmaceutical and healthcare companies, is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer.

The consumer healthcare business brings an added dynamic dimension to our
company, with well known brands like Panadol, NiQuitin, Sensodyne and
Aquafresh among others but, as with all our products, the driving force
behind our consumer healthcare business is science. With four dedicated
consumer healthcare R&D centres and consumer healthcare regulatory affairs,
the business takes scientific innovation as seriously as marketing excellence
and offers leading-edge capability in both. For company information, please
visit www.gsk.com.

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995, GSK cautions investors that any
forward-looking statements or projections made by GSK, including those
made in this announcement, are subject to risks and uncertainties that
may cause actual results to differ materially from those projected.
Factors that may affect GSK's operations are described under 'Risk
Factors' in the 'Business Review' in the company's Annual Report on Form
20-F for 2007.

    Registered in England & Wales:
    No. 3888792
    Registered Office:
    980 Great West Road
    Brentford, Middlesex
    TW8 9GS

    For further information please contact the alli Press Centre at
    +44(0)207-025-6418 or email alliteam@redconsultancy.com

    [1] Based on sales data from launch to October 2010

For further information please contact the alli Press Centre at +44(0)207-025-6418 or email alliteam at redconsultancy.com